TotalMarketCap

Inhibrx Biosciences

INBXNasdaq United StatesHealth CareBiotechnology: Biological Products (No Diagnostic Substances)

Market cap

$1.177 B

$80.00 -7.79%

Close of 6 Nov 2026

As of 6 Nov 2026, Inhibrx Biosciences (INBX) has a market capitalization of $1.18B. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$1.30M

#3438 by revenue

Earnings

-$140.1M

Loss-making

Shares outstanding

14,717,660

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →
  1. #42ImmunocoreIMCR$1.47B
  2. #43Taysha Gene TherapiesTSHA$1.35B
  3. #44Inhibrx BiosciencesINBX$1.18B
  4. #45Vor BiopharmaVOR$1.15B
  5. #46ImmaticsIMTX$930.0M

What if Inhibrx Biosciences were worth as much as…

Open the what-if tool →

Gold $28.2T

$1,918,571

Per share 23,982× higher

Bitcoin $1.53T

$103,810.53

Per share 1,298× higher

Apple $5.02T

$340,800.28

Per share 4,260× higher

Or at a round number

$2.00B$5.00B$10.0B$20.0B

Where these numbers come from

Share counts and financials for Inhibrx Biosciences are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.